New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
16:02 EDTPFE, GLYCGlycoMimetics receives $15M payment from Pfizer related to rivipansel
GlycoMimetics (GLYC) announced that Pfizer (PFE) has made a $15M payment to GlycoMimetics under the terms of the parties’ collaboration for the development of rivipansel. Under the collaboration, Pfizer plans to initiate a Phase 3 clinical trial of rivipansel, which will trigger an additional $20M milestone payment to GlycoMimetics upon the dosing of the first patient in the trial. The companies are currently developing rivipansel as a potential treatment for VOC of sickle cell disease.
News For GLYC;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
06:44 EDTPFEPfizer price target raised to $51 from $48 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss raised his price target for Pfizer (PFE) to $51 following yesterday's closure of the company's Hospira (HSP) acquisition. Purkiss now sees Pfizer's 2015-2019 adjusted earnings annual growth rate at 13%, versus the consensus at 9%. He sees a "compelling entry point" following the recent pullback and calls Pfizer his top pick in the U.S. Pharma group.
September 3, 2015
09:01 EDTPFEPfizer completes acquisition of Hospira
Subscribe for More Information
September 1, 2015
18:19 EDTPFEJudge says inclined to proceed with Pfizer lawsuit, WSJ reports
Subscribe for More Information
August 31, 2015
16:34 EDTGLYCGlycoMimetics issued composition of matter patent for GMI-1271
Subscribe for More Information
09:11 EDTPFEEuropean Society of Cardiology
Subscribe for More Information
August 27, 2015
17:38 EDTPFES&P announces changes to S&P 500 index
Subscribe for More Information
07:24 EDTPFEPfizer shares even more compelling after recent weakness, says Piper Jaffray
Subscribe for More Information
06:55 EDTPFEHospira sees merger closing on or about September 3
Hospira (HSP) said in a regulatory filing that on August 21, Hospira and Pfizer (PFE) received clearance from the U.S. FTC, relating to the pending merger of Hospira with Perkins Holding Company, a wholly-owned subsidiary of Pfizer. All required regulatory approvals have now been secured, though the merger remains conditioned upon the expiration of a post-clearance waiting period in one foreign jurisdiction. Hospira expects the merger to close on or about September 3.
August 26, 2015
07:32 EDTPFEPfizer launches Phase 3 trial of targeted therapy for breast cancer patients
Subscribe for More Information
06:16 EDTPFEAlvogen to acquire product portfolio from Pfizer for US market
Subscribe for More Information
August 25, 2015
14:16 EDTPFEMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
August 24, 2015
12:57 EDTPFEFTC requires Pfizer to sell rights to four products as condition of buying Hospira
Subscribe for More Information
08:16 EDTPFEBristol-Myers, Pfizer to present new data on Eliquis at ESC Congress 2015
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation and venous thromboembolism patient populations. In addition, data from the AEGEAN study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
08:01 EDTPFEPfizer receives clearance from FTC for Hospira acquisition
Subscribe for More Information
August 23, 2015
12:35 EDTPFEBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
08:01 EDTPFEPfizer says two Phase 3 Trumenba studies met primary endpoints
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use